Celltrion’s Remsia in spotlight

Published: 2013-09-04 06:59:00

Updated: 2013-09-04 06:59:00

Celltrion’s biosimilar monoclonal antibody Remsima (infliximab) is currently under the industry spotlight after the company gained market authorization from the European Commission on August 28.

The clinical report of Remsima, a biosimilar version of Remicade, was presented and praised as a re...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK